Webinar on June 22: Monoclonal Antibody Therapy for High Risk COVID Patients

Tuesday, June 22, 2-2:30PM EDT

Audience: Quality, Infection Preventionists, Pharmacy, Antimicrobial Stewardship Leaders, Laboratory and Physicians

Since their initial emergency authorization in November, monoclonal antibodies have been an important weapon in the fight against COVID-19. These products have proven to be effective at preventing hospitalization and death due to COVID-19 in some of the highest risk patients.

Alliant Quality is hosting a presentation titled, “Monoclonal Antibody Therapy for High Risk COVID Patients” on June 22 from 2-2:30PM EDT. This presentation will provide an overview of these products, the data behind their emergency authorization, and the clinical considerations around their use.

Learning Objectives:

  • Identity and review the currently authorized COVID-19 monoclonal antibody therapies and the requirements associated with their emergency use.
  • Demonstrate how the use of monoclonal antibodies can reduce hospitalization and death in those at highest risk for negative outcomes from COVID-19.
  • Share tools and resources available to providers and patients interested in monoclonal antibody therapy.

Featured Speaker:

Tim Davis, PharmD, BCNP, PMP
Eastern Region Pharmacist
Division of Public Health, Epidemiology Section
Public Health Preparedness and Response Branch
NC Department of Health and Human Services